Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered a research and development agreement to study and develop a dosage and time-release ketamine implant for the treatment of fibromyalgia. According to the announcement, the project will include analytical testing services as well as small batch preclinical … Continue reading InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Entry into Ketamine Implant Therapeutic Research Project